vs
Side-by-side financial comparison of CollPlant Biotechnologies Ltd (CLGN) and Sunlands Technology Group (STG). Click either name above to swap in a different company.
CollPlant Biotechnologies Ltd is the larger business by last-quarter revenue ($10.2M vs $10.1M, roughly 1.0× Sunlands Technology Group). CollPlant Biotechnologies Ltd runs the higher net margin — 56.6% vs 24.0%, a 32.6% gap on every dollar of revenue.
CollPlant Biotechnologies Ltd is a regenerative medicine company focused on developing and commercializing advanced products using its proprietary plant-derived human collagen technology. Its core offerings cover wound care, soft tissue repair, and aesthetic medicine solutions, targeting key markets across North America, Europe, and Israel, serving healthcare providers in dermatology, orthopedics and cosmetic care segments.
STG Partners, LLC (STG) is an American private equity firm and based in Menlo Park, California. Its predecessor, Symphony Technology Group ("Symphony") was founded in 2002 by Romesh Wadhwani, William Chisholm, and Bryan Taylor. In 2017, Symphony was reorganized as STG Partners. As of March 2025, STG Partners managed approximately $12 billion in 19 pooled investment vehicle for its clients. The firm itself has less than one billion dollars in assets.
CLGN vs STG — Head-to-Head
Income Statement — Q2 FY2023 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.2M | $10.1M |
| Net Profit | $5.8M | $2.4M |
| Gross Margin | 94.0% | 88.5% |
| Operating Margin | 55.7% | 26.5% |
| Net Margin | 56.6% | 24.0% |
| Revenue YoY | 15330.3% | — |
| Net Profit YoY | 234.5% | — |
| EPS (diluted) | $0.49 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $10.1M | ||
| Q2 25 | — | $9.3M | ||
| Q4 24 | — | $9.7M | ||
| Q2 24 | — | $10.0M | ||
| Q3 23 | — | $9.9M | ||
| Q2 23 | $10.2M | $10.0M |
| Q3 25 | — | $2.4M | ||
| Q2 25 | — | $1.4M | ||
| Q4 24 | — | $1.8M | ||
| Q2 24 | — | $2.2M | ||
| Q3 23 | — | $2.5M | ||
| Q2 23 | $5.8M | $3.3M |
| Q3 25 | — | 88.5% | ||
| Q2 25 | — | 85.2% | ||
| Q4 24 | — | 83.3% | ||
| Q2 24 | — | 85.2% | ||
| Q3 23 | — | 87.8% | ||
| Q2 23 | 94.0% | 88.7% |
| Q3 25 | — | 26.5% | ||
| Q2 25 | — | 15.2% | ||
| Q4 24 | — | 13.4% | ||
| Q2 24 | — | — | ||
| Q3 23 | — | 23.3% | ||
| Q2 23 | 55.7% | 29.6% |
| Q3 25 | — | 24.0% | ||
| Q2 25 | — | 15.4% | ||
| Q4 24 | — | 18.2% | ||
| Q2 24 | — | 21.5% | ||
| Q3 23 | — | 25.1% | ||
| Q2 23 | 56.6% | 33.0% |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | $0.31 | ||
| Q3 23 | — | — | ||
| Q2 23 | $0.49 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $22.3M | $15.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $36.0M | $17.7M |
| Total Assets | $41.6M | $41.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $15.1M | ||
| Q2 25 | — | — | ||
| Q4 24 | — | $15.6M | ||
| Q2 24 | — | $18.7M | ||
| Q3 23 | — | $16.5M | ||
| Q2 23 | $22.3M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | $1.5M | ||
| Q2 24 | — | $1.8M | ||
| Q3 23 | — | $2.2M | ||
| Q2 23 | — | — |
| Q3 25 | — | $17.7M | ||
| Q2 25 | — | $12.6M | ||
| Q4 24 | — | $10.7M | ||
| Q2 24 | — | $7.6M | ||
| Q3 23 | — | $2.5M | ||
| Q2 23 | $36.0M | — |
| Q3 25 | — | $41.2M | ||
| Q2 25 | — | $40.3M | ||
| Q4 24 | — | $42.4M | ||
| Q2 24 | — | $41.3M | ||
| Q3 23 | — | $40.0M | ||
| Q2 23 | $41.6M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | 0.14× | ||
| Q2 24 | — | 0.24× | ||
| Q3 23 | — | 0.86× | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
